Sugi Predict

Sugi Predict / Compounds / SCHEMBL2215587

SCHEMBL2215587

SCHEMBL2215587

[CH2]CCCCc1ccc2[nH]c3ccccc3c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.48
▸ KIF11 P52732 6/20 0.46
▸ ALDH1A1 P00352 6/20 0.45
▸ HSD17B10 Q99714 4/20 0.45
▸ GPR3 P46089 1/20 0.45
▸ KDM4E B2RXH2 4/20 0.42
▸ HPGD P15428 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ GABRP O00591 2/20 0.42
▸ GABRD O14764 2/20 0.42
▸ GABRA1 P14867 2/20 0.42
▸ GABRB1 P18505 2/20 0.42
▸ GABRG2 P18507 2/20 0.42
▸ GABRB3 P28472 2/20 0.42
▸ GABRA5 P31644 2/20 0.42
▸ GABRA3 P34903 2/20 0.42
▸ GABRA2 P47869 2/20 0.42
▸ GABRB2 P47870 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28193689 0.95 AHR (0.50) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL7031829 0.88 AHR (0.53) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL1723906 0.84 GABRP (0.56) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL31522705 0.84 GABRP (0.56) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL19768708 0.83 AHR (0.59) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL17779615 0.83 CTSV (0.58) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL9163470 0.83 CTSV (0.58) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL31522704 0.82 GABRP (0.61) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL4062550 0.82 GABRP (0.61) AHRKIF11ALDH1A1HSD17B10GPR3
SCHEMBL31522707 0.82 GABRP (0.61) AHRKIF11ALDH1A1HSD17B10GPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172441-A1 METHOD FOR SYNTHESIS OF ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-07-14 — — US claimed
US-8283855-B2 Method for synthesis of anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-10-09 — — US disclosed
US-8283855-B2 Method for synthesis of anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-10-09 — — US disclosed
JP-2011157353-A METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LAB CO LTD 2011-08-18 — — JP disclosed
US-20110172441-A1 METHOD FOR SYNTHESIS OF ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-07-14 — — US disclosed
US-20110172441-A1 METHOD FOR SYNTHESIS OF ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172441-A1 METHOD FOR SYNTHESIS OF ANTHRACENE DERIVATIVE CYP1A1, AHR, CYP2C9 AHR 2/4885KIF11 3694/4885ALDH1A1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.